- Home
- HCC vs PTGX Comparison
HCC vs PTGX Comparison
Compare HCC & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HCC | PTGX |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 5.4B |
| IPO Year | 2017 | 2016 |
Fundamental Metrics
Financial Performance| Metric | HCC | PTGX |
|---|---|---|
| Price | $101.00 | $82.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $76.40 | ★ $93.00 |
| AVG Volume (30 Days) | 750.1K | ★ 855.6K |
| Earning Date | 02-12-2026 | 02-20-2026 |
| Dividend Yield | ★ 0.32% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.67 | ★ 0.72 |
| Revenue | ★ $1,224,320,000.00 | $209,217,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $47.01 | $288.98 |
| P/E Ratio | $149.58 | ★ $113.84 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $38.00 | $33.70 |
| 52 Week High | $105.35 | $96.54 |
Technical Indicators
Market Signals| Indicator | HCC | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 79.63 | 43.54 |
| Support Level | $86.85 | $78.75 |
| Resistance Level | $105.35 | $87.44 |
| Average True Range (ATR) | 3.36 | 3.01 |
| MACD | 0.77 | -0.27 |
| Stochastic Oscillator | 77.05 | 36.81 |
Price Performance
Historical ComparisonAbout HCC Warrior Met Coal Inc.
Warrior Met Coal Inc is a U.S based company. It produces and exports of met coal that operates underground mines in Alabama. The company sells to steels manufacturers in Europe, Asia, and South America. Its mining operations consist of two underground met coal mines in Southern Appalachia's coal seam and other surface met and thermal coal mines. The Company generates ancillary revenues from the sale of natural gas extracted as a byproduct from the underground coal mines and royalty revenues from leased properties.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.